Compass Therapeutics LLC

Robert V Tighe, Iii

Ugur Eskiocak

Piotr Bobrowicz

Cheuk Lun Leung

Paul Widboom

Michael March Schmidt

Jason M Lajoie

The present disclosure relates to combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and PD-1 antagonists. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the combination.

Method of treating cancer using CD137 antibodies and PD-1 antagonists

The present disclosure relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and tumor antigen-targeting antibodies.

CD137 antibodies and tumor antigen-targeting antibodies and uses thereof

The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.

Agonist antibodies that bind human CD137 and uses thereof

CD137 antibodies and PD-1 antagonists and uses thereof

The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.

Growing community of inventors

Cambridge, MA, United States of America

Robert V Tighe, Iii